Abstracts tagged "Adalimumab"

Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Antoine P. Brezin¹, Phillippe Kestelyn², Joachim Van Calster³, Glenn J. Jaffe⁴, Jennifer E. Thorne⁵, David Scales⁶, Pablo Franco⁷, Andrew D. Dick^8,9,10, Quan Dong Nguyen¹¹, Eric B. Suhler^12,13, Anne Camez¹⁴, Alexandra P. Song¹⁵, Martina Kron¹⁴, Samir Tari¹⁵, James T. Rosenbaum^16,17 and Arnd Heiligenhaus¹⁸, ¹Université Paris Descartes, Hôpital Cochin, Paris, France, ²Ghent University Hospital, Ghent, Belgium, ³University Hospitals Leuven, Leuven, Belgium, ⁴Duke University, Durham, NC, ⁵Johns Hopkins Medical Institute, Baltimore, MD, ⁶University of Texas Health Science Center, San Antonio, TX, ⁷Organización Médica de Investigación (OMI), Buenos Aires, Argentina, ⁸National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, London, United Kingdom, ⁹University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ¹⁰University College London, Institute of Ophthalmology, London, United Kingdom, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ¹²VA Portland Health Care System, Portland, OR, ¹³Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ¹⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁵AbbVie Inc., North Chicago, IL, ¹⁶Devers Eye Institute, Legacy Hospital system, Portland, OR, ¹⁷Casey Eye Institute, Oregon Health & Science University, Portland, OR, ¹⁸Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…
Abstract Number: 2039 • 2015 ACR/ARHP Annual Meeting
Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis
John Sheppard¹, Avani D. Joshi², Manish Mittal², Keith Betts³, Samir Tari², Yanjun Bao² and Andrew D Dick⁴, ¹Virginia Eye Consultants and Eastern Virginia Medical School, Norfolk, VA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom
Background/Purpose: To compare the effects of adalimumab and placebo on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) in subjects requiring high dose corticosteroids…
Abstract Number: 2054 • 2015 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Stanley B. Cohen¹, Mark C. Genovese², Ernest H. Choy³, Fernando Perez-Ruiz⁴, Jose L. Pablos⁵, Nan Zhang⁶ and Primal Kaur⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁴Servicio de Reumatología, Vizcaya, Spain, ⁵Instituto de Investigacion Hospital, Madrid, Spain, ⁶Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical comparisons indicates that…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 2727 • 2015 ACR/ARHP Annual Meeting
BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
Christopher Wynne¹, Magdalena Petkova², Ferdinand Rombout³, Niklas Czeloth³, Mario Altendorfer³, Benjamin Lang⁴, Francois-Xavier Frapaise³ and Rod Ellis-Pegler⁵, ¹Christchurch Clinical Studies Trust, Christchurch, New Zealand, ²SGS, CPU Antwerpen, Antwerp, Belgium, ³Boehringer Ingelheim, Ingelheim, Germany, ⁴Boehringer Ingelheim, Biberach an der Riss, Germany, ⁵Auckland Clinical Studies Limited, Auckland, New Zealand
Background/Purpose: BI 695501 is a proposed adalimumab biosimilar currently in development and was evaluated for pharmacokinetic (PK) similarity to both US-licensed and EU-approved reference products.…
Abstract Number: 2745 • 2015 ACR/ARHP Annual Meeting
Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
Benjamin Chastek¹, James Harnett², Jeffrey R. Curtis³, Robert Gerber⁴, David Gruben⁴, Rui Song⁵ and Andrew Koenig⁶, ¹Optum Insight, Eden Prairie, MN, ²Pfizer Inc, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, Groton, CT, ⁵Optum Insight, Reston, VA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: In November 2012, the first oral Janus kinase (JAK) inhibitor tofacitinib was approved in the US for the treatment of RA with or without…
Abstract Number: 2836 • 2015 ACR/ARHP Annual Meeting
Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis
Filip van Den Bosch¹, Philip J. Mease², Joachim Sieper³, Dominique Baeten⁴, Nupun A. Varothai⁵, Aileen L. Pangan⁵ and In-Ho Song⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: ABILITY-2 has demonstrated the efficacy of adalimumab (ADA) vs. placebo (PBO) over 12 weeks (wk) in patients (pt) with peripheral spondyloarthritis (pSpA)1 and sustained…
Abstract Number: 5 • 2015 ACR/ARHP Annual Meeting
Prospective Study of the Effect of Treatment with Adalumumab in Angiogenesis in Moderate or Severe Psoriasis for a Period of 6 Months
Montserrat Santos-Gómez¹, Leyre Riancho-Zarrabeitia¹, Ricardo Blanco¹, Carmen Gonzalez-Vela², Jose L. Hernández³, Susana Armesto⁴, Marcos A González López⁴, Javier Loricera¹, Vanesa Calvo-Río¹, María Marcellán⁴, Marta Drake⁵, Sandra Hermana-Ramírez², Enar Pons⁵, Patricia Fuentevilla¹, Alfonso Corrales¹, Trinitario Pina¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Angiogenesis plays an important role in the pathogenesis of psoriasis. TNFa is an essential mediator that induces the expression of VEGF, which activates…
Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Alla Skapenko¹, Hendrik Schulze-Koops¹, Viswanath Devanarayan², Kenneth Idler³, Feng Hong⁴, Josef Smolen⁵, Arthur Kavanaugh⁶, Hartmut Kupper⁷ and Jeffrey F. Waring³, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²AbbVie Bioresearch Center, Worcester, MA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Bioresearch Center, Worchester, MA, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶University of California San Diego, La Jolla, CA, ⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…
Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Marc Schmalzing¹, Frank Behrens^2,3, Eva C. Scharbatke¹, Michaela Koehm^3,4, Bianca Wittig⁵, Gerd Greger⁶, Harald Burkhardt^2,7 and Hans-Peter Tony⁸, ¹Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ³Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁴Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶AbbVie GmbH & Co KG, Wiesbaden, Germany, ⁷Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁸Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 562 • 2014 ACR/ARHP Annual Meeting
Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy
Désirée M. van der Heijde¹, Joachim Sieper², Walter P. Maksymowych³, Dominique L. Baeten⁴, Yinglin Xia⁵, Jaclyn K. Anderson⁵ and Aileen L. Pangan⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) has been previously shown to be effective for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) patients (pts) in the ABILITY-1 trial.1 Week…

« Previous Page
1
…
8
9
10
11
12
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].